Barchart.com
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
1.6000 x 2 2.1000 x 1
Post-market by (Cboe BZX)
1.6700 +0.0600 (+3.73%) 03/21/25 [NASDAQ]
1.6000 x 2 2.1000 x 1
Post-market 1.6700 unch (unch) 16:10 ET
News & Headlines for Fri, Mar 21st, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update GlobeNewswire - Wed Mar 5, 6:00AM CST

TCRX : 1.6700 (+3.73%)
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference GlobeNewswire - Thu Feb 27, 6:00AM CST

TCRX : 1.6700 (+3.73%)
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference GlobeNewswire - Tue Feb 18, 6:00AM CST

TCRX : 1.6700 (+3.73%)
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium GlobeNewswire - Thu Dec 26, 2024

TCRX : 1.6700 (+3.73%)
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank GlobeNewswire - Mon Dec 23, 2024

TCRX : 1.6700 (+3.73%)
stethoscope with cartoon heart by Myriams-Fotos via Pixabay
2 "Strong Buy"-Rated Biotech Stocks With 303% to 446% Upside Potential Barchart - Tue Dec 17, 2024

While the upside is appealing, penny stocks carry some risks.

TCRX : 1.6700 (+3.73%)
$SPX : 5,667.56 (+0.08%)
SCPH : 3.00 (-0.33%)
Insider Purchase: 10% owner at $TCRX (TCRX) Buys 31,800 Shares Quiver Quantitative, Inc. - Tue Dec 17, 2024

Capital Management LP Lynx1, a 10% owner of $TCRX ($TCRX), bought 31,800 shares of the company on 12-12-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased...

TCRX : 1.6700 (+3.73%)
TScan Therapeutics Reports Positive Preliminary Results from ALLOHA Phase 1 Trial and Announces Upcoming Virtual KOL Event Quiver Quantitative, Inc. - Tue Dec 10, 2024

TScan Therapeutics reports positive Phase 1 trial results for TCR-T therapies in leukemia, with a KOL event scheduled.Quiver AI SummaryTScan Therapeutics, Inc. reported promising results from the ongoing...

TCRX : 1.6700 (+3.73%)
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHAâ„¢ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition GlobeNewswire - Mon Dec 9, 2024

TCRX : 1.6700 (+3.73%)
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years GlobeNewswire - Thu Dec 5, 2024

TCRX : 1.6700 (+3.73%)

Barchart Exclusives

Nvidia CEO Jensen Huang Is Betting on $1 Trillion in Data Center Buildouts By 2028. Here’s the Top Stock to Buy. Barchart - Sat Mar 22, 12:00PM CDT
The stock of Nvidia’s only genuine competitor could benefit from the upcoming data center boom. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals
Wed, Mar 26, 2025 5:00 PM UTC
Reserve Your Spot